Literature DB >> 29404680

The contribution of comorbidities to mortality in hospitalized patients with heart failure.

Oliver Riedel1, C Ohlmeier2,3, D Enders2, A Elsässer4, D Vizcaya5, A Michel5, S Eberhard6, N Schlothauer7, J Berg8, E Garbe2.   

Abstract

BACKGROUND: Heart failure (HF) with reduced ejection fraction (HFrEF) has a worse prognosis than HF with preserved EF (HFpEF). The study aimed to evaluate whether different comorbidity profiles of HFrEF- and HFpEF-patients or HF-specific mechanisms contribute to a greater extent to this difference.
METHODS: We linked data from two health insurances to data from a cardiology clinic hospital information system. Patients with a hospitalization with HF in 2005-2011, categorized as HFrEF (EF < 45%) or HFpEF (EF ≥ 45%), were propensity score (PS) matched to controls without HF on comorbidites and medication to assure similar comorbidity profiles of patients and their respective controls. The balance of the covariates in patients and controls was compared via the standardized difference (SDiff). Age-standardized 1-year mortality rates (MR) with 95% confidence intervals (CI) were calculated.
RESULTS: 777 HFrEF-patients (1135 HFpEF-patients) were PS-matched to 3446 (4832) controls. Balance between patients and controls was largely achieved with a SDiff < 0.1 on most variables considered. The age-standardized 1-year MRs per 1000 persons in HFrEF-patients and controls were 267.8 (95% CI 175.9-359.8) and 86.1 (95% CI 70.0-102.3). MRs in HFpEF-patients and controls were 166.2 (95% CI 101.5-230.9) and 61.5 (95% CI 52.9-70.1). Thus, differences in MRs between patients and their controls were higher for HFrEF (181.7) than for HFpEF (104.7).
CONCLUSIONS: Given the similar comorbidity profiles between HF-patients and controls, the higher difference in mortality rates between HFrEF-patients and controls points more to HF-specific mechanisms for these patients, whereas for HFpEF-patients a higher contribution of comorbidity is suggested by our results.

Entities:  

Keywords:  Claims data; Comorbidities; Heart failure; Mortality

Mesh:

Year:  2018        PMID: 29404680     DOI: 10.1007/s00392-018-1210-x

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  36 in total

Review 1.  Frequent non-cardiac comorbidities in patients with chronic heart failure.

Authors:  Ulf Dahlström
Journal:  Eur J Heart Fail       Date:  2005-03-16       Impact factor: 15.534

2.  Sex differences in in-hospital mortality in acute decompensated heart failure with reduced and preserved ejection fraction.

Authors:  Eileen M Hsich; Maria V Grau-Sepulveda; Adrian F Hernandez; Eric D Peterson; Lee H Schwamm; Deepak L Bhatt; Gregg C Fonarow
Journal:  Am Heart J       Date:  2012-03       Impact factor: 4.749

3.  Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND.

Authors:  Frank P Brouwers; Rudolf A de Boer; Pim van der Harst; Adriaan A Voors; Ron T Gansevoort; Stephan J Bakker; Hans L Hillege; Dirk J van Veldhuisen; Wiek H van Gilst
Journal:  Eur Heart J       Date:  2013-03-06       Impact factor: 29.983

Review 4.  Epidemiology and clinical course of heart failure with preserved ejection fraction.

Authors:  Carolyn S P Lam; Erwan Donal; Elisabeth Kraigher-Krainer; Ramachandran S Vasan
Journal:  Eur J Heart Fail       Date:  2010-08-03       Impact factor: 15.534

Review 5.  Treatment of heart failure with normal ejection fraction: an inconvenient truth!

Authors:  Walter J Paulus; Joris J M van Ballegoij
Journal:  J Am Coll Cardiol       Date:  2010-02-09       Impact factor: 24.094

6.  Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.

Authors:  Michael R MacDonald; Mark C Petrie; Fumi Varyani; Jan Ostergren; Eric L Michelson; James B Young; Scott D Solomon; Christopher B Granger; Karl Swedberg; Salim Yusuf; Marc A Pfeffer; John J V McMurray
Journal:  Eur Heart J       Date:  2008-04-14       Impact factor: 29.983

Review 7.  Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis.

Authors:  Karen Hogg; Karl Swedberg; John McMurray
Journal:  J Am Coll Cardiol       Date:  2004-02-04       Impact factor: 24.094

8.  Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry.

Authors:  Gregg C Fonarow; Wendy Gattis Stough; William T Abraham; Nancy M Albert; Mihai Gheorghiade; Barry H Greenberg; Christopher M O'Connor; Jie Lena Sun; Clyde W Yancy; James B Young
Journal:  J Am Coll Cardiol       Date:  2007-08-06       Impact factor: 24.094

Review 9.  Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review.

Authors:  Muthiah Vaduganathan; Alexander Michel; Kathryn Hall; Claire Mulligan; Savina Nodari; Sanjiv J Shah; Michele Senni; Marco Triggiani; Javed Butler; Mihai Gheorghiade
Journal:  Eur J Heart Fail       Date:  2015-12-03       Impact factor: 15.534

10.  Irbesartan in patients with heart failure and preserved ejection fraction.

Authors:  Barry M Massie; Peter E Carson; John J McMurray; Michel Komajda; Robert McKelvie; Michael R Zile; Susan Anderson; Mark Donovan; Erik Iverson; Christoph Staiger; Agata Ptaszynska
Journal:  N Engl J Med       Date:  2008-11-11       Impact factor: 91.245

View more
  10 in total

1.  Echocardiographic changes in elderly patients with heart failure with reduced ejection fraction after sacubitril-valsartan treatment.

Authors:  Wei Gu; Chuangye Xu; Zhao Li; Zhi-Zhong Li
Journal:  Cardiovasc Diagn Ther       Date:  2021-10

Review 2.  [Update on heart failure].

Authors:  J Wintrich; I Kindermann; M Böhm
Journal:  Herz       Date:  2018-06-05       Impact factor: 1.443

Review 3.  Management strategies in heart failure with preserved ejection fraction.

Authors:  Jan Wintrich; Amr Abdin; Michael Böhm
Journal:  Herz       Date:  2022-05-06       Impact factor: 1.740

4.  Metabolic modulation predicts heart failure tests performance.

Authors:  Daniel Contaifer; Leo F Buckley; George Wohlford; Naren G Kumar; Joshua M Morriss; Asanga D Ranasinghe; Salvatore Carbone; Justin M Canada; Cory Trankle; Antonio Abbate; Benjamin W Van Tassell; Dayanjan S Wijesinghe
Journal:  PLoS One       Date:  2019-06-20       Impact factor: 3.240

5.  Non-cardiac comorbidities and mortality in patients with heart failure with reduced vs. preserved ejection fraction: a study using the Swedish Heart Failure Registry.

Authors:  Constantinos Ergatoudes; Maria Schaufelberger; Bert Andersson; Aldina Pivodic; Ulf Dahlström; Michael Fu
Journal:  Clin Res Cardiol       Date:  2019-02-20       Impact factor: 5.460

6.  Anabolic Hormones Deficiencies in Heart Failure With Preserved Ejection Fraction: Prevalence and Impact on Antioxidants Levels and Myocardial Dysfunction.

Authors:  Carmine Bruno; Andrea Silvestrini; Rodolfo Calarco; Angela M R Favuzzi; Edoardo Vergani; Maria Anna Nicolazzi; Claudia d'Abate; Elisabetta Meucci; Alvaro Mordente; Raffaele Landolfi; Antonio Mancini
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-12       Impact factor: 5.555

Review 7.  Current Understanding of Molecular Pathophysiology of Heart Failure With Preserved Ejection Fraction.

Authors:  Heidi Budde; Roua Hassoun; Andreas Mügge; Árpád Kovács; Nazha Hamdani
Journal:  Front Physiol       Date:  2022-07-07       Impact factor: 4.755

Review 8.  Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future.

Authors:  Jan Wintrich; Ingrid Kindermann; Christian Ukena; Simina Selejan; Christian Werner; Christoph Maack; Ulrich Laufs; Carsten Tschöpe; Stefan D Anker; Carolyn S P Lam; Adriaan A Voors; Michael Böhm
Journal:  Clin Res Cardiol       Date:  2020-03-31       Impact factor: 5.460

9.  Mode of presentation and mortality amongst patients hospitalized with heart failure? A report from the First Euro Heart Failure Survey.

Authors:  Ahmad Shoaib; M Farag; J Nolan; A Rigby; A Patwala; M Rashid; C S Kwok; R Perveen; A L Clark; M Komajda; J G F Cleland
Journal:  Clin Res Cardiol       Date:  2018-10-25       Impact factor: 5.460

10.  Obstructive sleep apnoea but not central sleep apnoea is associated with left ventricular remodelling after acute myocardial infarction.

Authors:  Christoph Fisser; Kristina Götz; Andrea Hetzenecker; Kurt Debl; Florian Zeman; Okka W Hamer; Florian Poschenrieder; Claudia Fellner; Stefan Stadler; Lars S Maier; Michael Pfeifer; Stefan Buchner; Michael Arzt
Journal:  Clin Res Cardiol       Date:  2020-06-09       Impact factor: 5.460

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.